
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. is advancing its clinical-stage candidate PMN310, which is demonstrating a favorable safety profile, particularly regarding amyloid-related imaging abnormalities (ARIA), compared to existing marketed anti-amyloid therapies. The ongoing Phase Ib PRECISE-AD study has successfully achieved over 85% enrollment, indicating solid momentum towards clinical milestones, and the recent data show promise in preserving memory and learning in Alzheimer's disease mouse models. The Alzheimer's market presents a substantial commercial opportunity, reinforcing a positive outlook on the potential growth and market impact of ProMIS Neurosciences' innovative therapeutic approaches.
Bears say
ProMIS Neurosciences reported a significant net loss of $11.6 million for 3Q25, indicating ongoing financial strain as the company remains in a clinical stage without generating positive cash flow. The company faces multiple risks, including the potential inability to demonstrate the safety and efficacy of its lead candidate, PMN310, amidst high competition and market challenges, which could hinder its path to regulatory approval. Additionally, concerns regarding the need for future financing may exacerbate dilution risks for current shareholders, further contributing to the negative outlook on the stock.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares